Evidence map›Paper›PMID 37417556›Full record

ReviewInvestigative and clinical urology2023

Regenerative therapies as a potential treatment of erectile dysfunction.

Doo Yong Chung, Ji-Kan Ryu, Guo Nan Yin

Open access · diamondAbstract readReview
In one paragraph

Review in Investigative and clinical urology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Doo Yong Chung *National Research Center for Sexual Medicine and Department of Urology, Inha University College of Medicine, Incheon, Korea.ORCID 0000-0001-8614-5742
Ji-Kan Ryu *National Research Center for Sexual Medicine and Department of Urology, Inha University College of Medicine, Incheon, Korea.ORCID 0000-0003-0025-6025
Guo Nan YinNational Research Center for Sexual Medicine and Department of Urology, Inha University College of Medicine, Incheon, Korea. 217052@inha.ac.kr.ORCID 0000-0002-2512-7337
Inha University · KR

Funding

Inha
6 · The paper itself

Abstract

Erectile dysfunction (ED) is the most common sexual dysfunction disease in adult males. ED can be caused by many factors, such as vascular disease, neuropathy, metabolic disturbances, psychosocial causes, and side effects of medications. Although current oral phosphodiesterase type 5 inhibitors can achieve a certain effect, they cause temporary dilatation of blood vessels with no curative treatment effects. Emerging targeted technologies, such as stem cell therapy, protein therapy, and low-intensity extracorporeal shock wave therapy (Li-ESWT), are being used to achieve more natural and long-lasting effects in treating ED. However, the development and application of these therapeutic methods are still in their infancy, and their pharmacological pathways and specific mechanisms have not been fully discovered. This article reviews the preclinical basic research progress of stem cells, proteins, and Li-ESWT therapy, as well as the current status of clinical application of Li-ESWT therapy.

Indexed as

Erectile DysfunctionExtracorporeal Shockwave TherapyHumansMalePhosphodiesterase 5 InhibitorsStem CellsPhosphodiesterase 5 InhibitorsErectile dysfunctionExtracorporeal shockwave therapiesProteinsRegenerative medicineStem cell

Identifiers

PMID37417556
PMCPMC10330409
OpenAlexW4382993030

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.